Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Meet Medicilon at ACS FALL 2023

2023-08-07
|
Page View:

ACSFALL2023-kv

Medicilon is excited to exhibit at ACS FALL 2023.

Our Business Development team will be waiting at ACS Booth#244. Please stop by and explore our services and capabilities. Meanwhile, our EVP and Head of IDSU, Dr. Xuedong Dai, has been invited to attend and exhibit at the conference.  He will be able to exchange ideas with attendees.

We look forward to meeting you in person to discuss how our services and capabilities would support your current research needs and expedite your drug discovery and development programs.See you soon in San Francisco!


Date: August 13-17, 2023

Location: San Francisco, CA & Hybrid

Medicilon Booth: #244

Meet with Medicilon


Subject丨ACS FALL 2023


Click to switch


About ACS FALL 2023

ACS FALL 2023 theme this year is 'Harnessing the Power of Data'. Thousands of chemistry professionals will meet to share ideas and advance scientific and technical knowledge.

  • During the Keynote Events on August 13, experts from academia and industry to highlight current advances in data storage, retrieval and use as well as how data will be used to advance the chemical enterprise in the future. Those interested in chemical drug discovery can especially focus on the topic 'What Artificial Intelligence Can Do to Accelerate Chemical Discovery'.

  • Before the conference, the organizers will set up an in-person workshop to discuss 'Multidisciplinary Fundamentals of Drug Discovery and Development'.

  • More than 1,000 papers will be presented during the conference and explore cutting-edge chemistry. Some of them are related to medicinal chemistry.


About ACS

Founded in 1876 and chartered by the U.S. Congress, ACS is one of the world’s largest scientific organizations with more than 173,000 individuals in our global community across 140 countries. Our mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and its people. Our vision is to improve all people’s lives through the transforming power of chemistry.
As a non-profit scientific organization with more than 140 years’ experience, ACS is a champion for chemistry, its practitioners and our global community of members.


About Medicilon

Medicilon is an integrated contract research organization (CRO), providing comprehensive one-stop new drug R&D services from ideal to pre-IND enabling stage for pharmaceutical enterprises and scientific research institutions around the world. We constantly develop new technology platform to grow with our global clients for their demanding for innovation and drug research. With our over 19 years experience in serving global pharmaceutical and novel drug discovery industries, we have built an integrated technical platform covering key technologies in small molecule and large molecuredrug discovery, in vivo and in vitro pharmacology research, and preclinical IND enabling research, to support drug research and development in today’s dynamic pharmaceutical  industry.

19+

More Than 19 Years of Experience in New Drug R&D

330+

Projects Successfully Approved with NMPA, FDA, EMA, and TGA

1,840+

Active Clients Worldwide

3,200+

New Drug Discovery Scientists and Service Personnel

84,600+

Square Meters of Laboratory Floor Space


Guest

Xuedong Dai, Ph.D Executive VP and Head of IDSU

As a doctor of organic chemistry then as a post doctoral researcher at the Massachusetts Institute of Technology, Xuedong has been deeply engaged in the research and development of chemical drugs for central nervous system diseases, infectious diseases and tumor diseases for more than 20 years. Xuedong has a deep understanding and rich practical experience in the process of drug discovery, including the determination and optimization of precursor compounds, and the successful development of high-quality clinical candidate compounds. Dr. Xuedong Dai has been involved in leading the development of marketed drugs such as HORIZANT®/REGNITE®; clinical drugs such as JNJ-75276617 and clinical candidates such as ARBACLOFEN PLACARBIL, XP21279, XP23829. Prior to joining Medicilon, Dr. Dai served as an executive at Xi'an Janssen, Pfeiffer Biotech, GSK, Xenoport and other well-known domestic and international pharmaceutical companies and CROs. He has an excellent project management record and extensive management experience.


Medicilon Chemistry Research Services

With the rapid development of the global pharmaceutical market and the division of labor in the pharmaceutical industry, the chain is becoming more and more refined, making specialized outsourcing in the pharmaceutical industry an important strategic choice for pharmaceutical companies. In the early stages of new drug development, FTE (Full-time equivalent) is often used by drug discovery companies to synthesize the required structural fragments and/or potential candidate compounds to accelerate the drug screening process.Medicilon provides comprehensive chemistry research services covering all stages of your project requirements, and customers can cooperate with us through the FFS (Fee for Service) or FTE (Full-time Equivalent Service) models.

Medicilon Chemistry Services.jpg

#chemical #AI #drugdiscovery

Share:
Return
Relevant newsRelevant news